Unknown

Dataset Information

0

Accelerated suppression of primary Epstein-Barr virus infection in HIV-infected infants initiating lopinavir/ritonavir-based versus nevirapine-based combination antiretroviral therapy.

ABSTRACT: We compared primary Epstein-Barr virus (EBV) infection and suppression between Kenyan human immunodeficiency virus-infected infants starting nevirapine-based vs lopinavir/ritonavir-based antiretroviral regimens. Although the rate of EBV infection was similar between groups, infants receiving lopinavir/ritonavir suppressed EBV more rapidly. Our findings suggest that specific antiretrovirals may potentially impact the risk of future EBV-associated malignancies.

SUBMITTER: Slyker JA 

PROVIDER: S-EPMC3982841 | biostudies-literature | 2014 May

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Accelerated suppression of primary Epstein-Barr virus infection in HIV-infected infants initiating lopinavir/ritonavir-based versus nevirapine-based combination antiretroviral therapy.

Slyker Jennifer A JA   Casper Corey C   Tapia Kenneth K   Richardson Barbra B   Bunts Lisa L   Huang Meei-Li ML   Wamalwa Dalton D   Benki-Nugent Sarah S   John-Stewart Grace G  

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20140218 9

We compared primary Epstein-Barr virus (EBV) infection and suppression between Kenyan human immunodeficiency virus-infected infants starting nevirapine-based vs lopinavir/ritonavir-based antiretroviral regimens. Although the rate of EBV infection was similar between groups, infants receiving lopinavir/ritonavir suppressed EBV more rapidly. Our findings suggest that specific antiretrovirals may potentially impact the risk of future EBV-associated malignancies. ...[more]

Similar Datasets

Unknown First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting.
| S-EPMC4004638 | biostudies-literature
Unknown The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment.
| S-EPMC3317955 | biostudies-literature
Unknown Nevirapine- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV-Infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial.
| S-EPMC5036919 | biostudies-literature
Unknown Nevirapine Resistance in Previously Nevirapine-Unexposed HIV-1-Infected Kenyan Infants Initiating Early Antiretroviral Therapy.
| S-EPMC4533021 | biostudies-literature
Unknown Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children.
| S-EPMC3443859 | biostudies-literature
Unknown Metabolic effects of initiating lopinavir/ritonavir-based regimens among young children.
| S-EPMC6170714 | biostudies-literature
Unknown Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment.
| S-EPMC3927631 | biostudies-literature
Unknown Costs of Care of HIV-Infected Children Initiating Lopinavir/Ritonavir-Based Antiretroviral Therapy before the Age of Two in Cote d'Ivoire.
| S-EPMC5147813 | biostudies-literature
Unknown Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmission.
| S-EPMC4166566 | biostudies-other
Unknown Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in Sub-Saharan Africa: A5208 (OCTANE).
| S-EPMC4109714 | biostudies-literature